论文部分内容阅读
目的:观察白三烯受体拮抗剂在咳嗽变异性哮喘病症治疗中的疗效。方法:回顾分析我院210例咳嗽变异性哮喘患者的临床资料,按照患者治疗方案差异分为观察组和对照组,每组105例,观察组采用白三烯受体拮抗剂进行治疗,对照组患者使用常规激素吸入治疗,对比两组患者的治疗结果。结果:完成治疗后,观察组患者的临床疗效明显高于对照组,P<0.05,具有显著统计学差异,观察组患者的治疗时间更短,且患者复发更少,临床效果优异。结论:针对咳嗽变异性哮喘,在治疗时,可以采用白三烯受体拮抗剂进行治疗,提高患者的治疗有效率,减少患者的痛苦,提高治疗效果,临床值得推广使用。
Objective: To observe the efficacy of leukotriene receptor antagonist in the treatment of cough variant asthma. Methods: The clinical data of 210 patients with cough variant asthma in our hospital were retrospectively analyzed. According to the patients’ treatment plans, the patients were divided into observation group and control group, with 105 cases in each group. The observation group was treated with leukotriene receptor antagonist and the control group Patients were treated with conventional hormonal inhalation, comparing treatment outcomes in both groups. Results: After the completion of treatment, the clinical efficacy of the observation group was significantly higher than that of the control group, P <0.05, with significant statistical difference, the observation group patients with shorter treatment time, and patients with less recurrence, the clinical effect is excellent. Conclusions: In the treatment of cough variant asthma, leukotriene receptor antagonist can be used to treat patients with cough variant asthma, which can improve the treatment efficiency, reduce the patient’s pain and improve the therapeutic effect. It is worth to be used clinically.